- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hereditary angioedema
- Meeting Date: July 2020
- Public Summary Document (PSD) July 2020 PBAC Meeting - (PDF 1427KB)
- Public Summary Document (PSD) July 2020 PBAC Meeting - (Word 145KB)
Lanadelumab – July 2020
Lanadelumab: Solution for subcutaneous injection 300 mg in 2 mL; Takhzyro®
Last updated
13 November 2020